Clinical Trials Arena July 25, 2024
GlobalData

Newpath Partners spearheaded the funding round, which saw contributions from other new investors.

Autobahn Therapeutics has secured $100 in an oversubscribed Series C financing round for the commencement of two Phase II clinical trials of ABX-002 to treat major depressive disorder (MDD) and bipolar disorder depression.

Newpath Partners spearheaded the funding round, which saw contributions from new investors, which included Monograph Capital, Canaan Partners and Insight Partners.

All of Autobahn’s existing investors also participated, among them are founding investors ARCH Venture Partners and Blue Owl Healthcare Opportunities, BVF Partners, Samsara BioCapital, Invus, Biogen, Pfizer Ventures, Bristol Myers Squibb, Section 32, GT Healthcare Capital Partners and Alexandria Venture Investments.

A selective thyroid hormone beta receptor (TRβ) agonist, ABX-002 has shown promise...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Clinical Trials, Investments, Mental Health, Provider, Trends
Related Articles:
A Look at State Efforts to Ban Cellphones in Schools and Implications for Youth Mental Health
Q&A: Researcher discusses why kids are struggling with anxiety more than ever
Risky combinations of psychiatric drugs prescribed for young patients
Missed Opportunities: Nearly 25% of Overdose Deaths Had Chance for Intervention
Surgeon General issues advisory on mental health and well-being of parents

Share This Article